Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 262

1.

Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia.

Sula M, Bacher U, Oppliger Leibundgut E, Mansouri Taleghani B, Novak U, Pabst T.

Bone Marrow Transplant. 2019 Dec 3. doi: 10.1038/s41409-019-0762-3. [Epub ahead of print] No abstract available.

PMID:
31796871
2.

Post remission consolidation by autologous HCT for AML in CR1, negative implications for subsequent allogeneic HCT in CR2. A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Passweg JR, Labopin M, Christopeit M, Cornelissen J, Pabst T, Socié G, Russel N, Yakoub-Agha I, Blaise D, Gedde-Dahl T, Labussière-Wallet H, Malladi R, Forcade E, Maury S, Polge E, Lanza F, Gorin NC, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Nov 20. pii: S1083-8791(19)30788-8. doi: 10.1016/j.bbmt.2019.11.021. [Epub ahead of print]

PMID:
31759159
3.

Detection of rare reciprocal RUNX1 rearrangements by next-generation sequencing in acute myeloid leukemia.

Flach J, Shumilov E, Joncourt R, Porret N, Tchinda J, Legros M, Scarpelli I, Hewer E, Novak U, Schoumans J, Bacher U, Pabst T.

Genes Chromosomes Cancer. 2019 Nov 22. doi: 10.1002/gcc.22829. [Epub ahead of print]

PMID:
31756777
4.

A simple acute phase protein score to predict long-term survival in patients with acute myeloid leukemia.

Heini AD, Hugo R, Berger MD, Novak U, Bacher U, Pabst T.

Hematol Oncol. 2019 Nov 21. doi: 10.1002/hon.2696. [Epub ahead of print]

PMID:
31755141
5.

Rebound Thrombocytosis after Induction Chemotherapy is a Strong Biomarker for Favorable Outcome in AML Patients.

Schnell BR, Seipel K, Bacher U, Jeker B, Mueller BU, Banz Y, Novak U, Pabst T.

Hemasphere. 2019 Mar 20;3(2):e180. doi: 10.1097/HS9.0000000000000180. eCollection 2019 Apr.

6.

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients.

Shumilov E, Novak U, Jeker B, Mansouri Taleghani B, Bacher U, Pabst T.

Hemasphere. 2019 Feb 8;3(2):e176. doi: 10.1097/HS9.0000000000000176. eCollection 2019 Apr. No abstract available.

7.

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia.

Seipel K, Schmitter K, Bacher U, Pabst T.

Cancers (Basel). 2019 Nov 12;11(11). pii: E1779. doi: 10.3390/cancers11111779.

8.

Immunoadsorption and autologous transplantation for life-threatening primary antiphospholipid syndrome.

Angelillo-Scherrer A, Mansouri Taleghani B, Förger F, Baerlocher GM, Pabst T, Pöllinger A, Banz Y, Geiser T, Kremer Hovinga JA, Rovó A.

Blood Adv. 2019 Sep 10;3(17):2664-2667. doi: 10.1182/bloodadvances.2019000465. No abstract available.

9.

Autologous stem cell transfusions on multiple days in patients with multiple myeloma-Does it matter?

Moser S, Bacher U, Jeker B, Mansouri Taleghani B, Betticher D, Ruefer A, Egger T, Novak U, Pabst T.

Hematol Oncol. 2019 Sep 4. doi: 10.1002/hon.2673. [Epub ahead of print] No abstract available.

PMID:
31483507
10.

Synthesis, Structure, and Hydrogenolysis of Pyridine Dicarbene Iron Dialkyl Complexes.

Rummelt SM, Darmon JM, Yu RP, Viereck P, Pabst TP, Turner ZR, Margulieux GW, Gu S, Chirik PJ.

Organometallics. 2019 Aug 26;38(16):3159-3168. doi: 10.1021/acs.organomet.9b00382. Epub 2019 Aug 9.

PMID:
31481822
11.

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10).

Hitz F, Kraus M, Pabst T, Hess D, Besse L, Silzle T, Novak U, Seipel K, Rondeau S, Stüdeli S, Vilei SB, Samaras P, Mey U, Driessen C; Swiss Group for Clinical Cancer Research SAKK.

Blood Cancer J. 2019 Aug 27;9(9):70. doi: 10.1038/s41408-019-0228-2.

12.

Cobalt-Catalyzed Borylation of Fluorinated Arenes: Thermodynamic Control of C(sp2)-H Oxidative Addition Results in ortho-to-Fluorine Selectivity.

Pabst TP, Obligacion JV, Rochette É, Pappas I, Chirik PJ.

J Am Chem Soc. 2019 Sep 25;141(38):15378-15389. doi: 10.1021/jacs.9b07984. Epub 2019 Sep 16.

PMID:
31449749
13.

Molecular minimal residual disease negativity and decreased stem cell mobilization potential predict excellent outcome after autologous transplant in NPM1 mutant acute myeloid leukemia.

De Santiago de Benito A, Jeker B, Gfeller E, Porret N, Banz Y, Novak U, Bacher U, Pabst T.

Haematologica. 2019 May 23. pii: haematol.2019.216457. doi: 10.3324/haematol.2019.216457. [Epub ahead of print]

14.

Chromatographic behavior of bivalent bispecific antibodies on cation exchange columns. I. Experimental observations and phenomenological model.

Kimerer LK, Pabst TM, Hunter AK, Carta G.

J Chromatogr A. 2019 Sep 13;1601:121-132. doi: 10.1016/j.chroma.2019.04.012. Epub 2019 Apr 21.

PMID:
31056270
15.

Chromatographic behavior of bivalent bispecific antibodies on cation exchange columns. II. Biomolecular perspectives.

Kimerer LK, Pabst TM, Hunter AK, Carta G.

J Chromatogr A. 2019 Sep 13;1601:133-144. doi: 10.1016/j.chroma.2019.04.013. Epub 2019 Apr 9.

PMID:
31054833
16.

Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML.

Shumilov E, Flach J, Joncourt R, Porret N, Wiedemann G, Novak U, Gfeller E, Jeker B, Amstutz U, Pabst T, Bacher U.

Leuk Lymphoma. 2019 Oct;60(10):2588-2590. doi: 10.1080/10428194.2019.1585838. Epub 2019 Apr 18. No abstract available.

PMID:
30998101
17.

Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.

Samaras P, Bargetzi M, Betticher DC, Driessen C, Duchosal MA, Heim D, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Schmidt A, Taverna C, Zander T, Renner C.

Swiss Med Wkly. 2019 Apr 3;149:w20031. doi: 10.4414/smw.2019.20031. eCollection 2019 Mar 25.

18.

Improved survival rates of AML patients following admission to the intensive care unit.

Fassbind P, Jeker B, Mueller BU, Bacher U, Zimmerli S, Endrich O, Gahl B, Novak U, Pabst T.

Leuk Lymphoma. 2019 Oct;60(10):2423-2431. doi: 10.1080/10428194.2019.1594213. Epub 2019 Apr 3.

PMID:
30943056
19.

Process optimization and protein engineering mitigated manufacturing challenges of a monoclonal antibody with liquid-liquid phase separation issue by disrupting inter-molecule electrostatic interactions.

Du Q, Damschroder M, Pabst TM, Hunter AK, Wang WK, Luo H.

MAbs. 2019 May/Jun;11(4):789-802. doi: 10.1080/19420862.2019.1599634. Epub 2019 Apr 14.

PMID:
30913985
20.

High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.

Prediletto I, Farag SA, Bacher U, Jeker B, Mansouri Taleghani B, Brégy R, Zander T, Betticher D, Egger T, Novak U, Pabst T.

Bone Marrow Transplant. 2019 Dec;54(12):1923-1925. doi: 10.1038/s41409-019-0508-2. Epub 2019 Mar 19. No abstract available.

PMID:
30890768

Supplemental Content

Loading ...
Support Center